Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ULBP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ULBP2 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View ULBP2 Products |
| Gene Delivery | ULBP2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Optimized for surface expression. |
View ULBP2 Products |
| Benchmark Ab | Anti-ULBP2 Recombinant Antibody Recombinant positive control derived from clinical-grade reference sequences. |
View ULBP2 Products |
| Validator | ULBP2 siRNA Set Target-specific knockdown pool for functional assay validation. |
View ULBP2 Products |
| Related Target A | NKG2D Primary cognate receptor for ULBP2. Critical for binding affinity and activation kinetics assays. |
View NKG2D Products |
| Related Target B | MICA Parallel NKG2D ligand. Essential for selectivity screening and cross-reactivity profiling. |
View MICA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NKG2D Receptor Binding Kinetics | HEK293 expressed ULBP2 ECD-Fc preserves native post-translational modifications, ensuring accurate SPR/BLI binding constants. |
| Shedding Resistance Screening | Lentivirus-ready full-length ULBP2 constructs allow rapid generation of stable target cells to screen for metalloproteinase (ADAM10/17) cleavage inhibitors. |
| Subfamily Cross-Reactivity | Sequence-verified NKG2D ligand panel (MICA/B, ULBP1-6) available for high-throughput specificity profiling. |
| Lack of Controls | Inclusion of sequence-verified clinical benchmark antibodies for assay standardization. |
| False Positives | Sequence-verified siRNA sets included to confirm target-specific phenotypic knockdown. |
Live ULBP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ULBP2-targeted therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to multi-specific NK cell engagers (NKCEs) and CAR-NK therapies. As first-generation NKG2D-based therapies navigate clinical trials, the next wave of R&D is targeting the prevention of ULBP2 shedding—a key mechanism of tumor immune evasion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engagers (BiKE/TriKE) | Innate Pharma, Affimed | Solid Tumors, AML | NKG2D binding kinetics and off-target profiling (Requires high-purity ECD-Fc proteins) |
| CAR-NK / CAR-T | Celyad Oncology, NKarta | Colorectal Cancer, Hematological Malignancies | Cytolytic assay validation (Requires Lentivirus for stable target cell line construction) |
| Shedding-Inhibiting mAbs | Academic Institutes, Biotech Startups | Advanced Epithelial Ovarian/Prostate Cancer | Cleavage inhibition assays (Requires sequence-verified full-length surface expression) |